What are checkpoint inhibitors and how do they work

May 19, 2026Navis AI

Ask Navis about your situation

This answer is general. Get one about your specific case — no signup, answered right here.

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Understanding Checkpoint Inhibitors

Checkpoint inhibitors are a type of immunotherapy drug that helps your immune system recognize and attack cancer cells. Let me explain how they work and why they're important in cancer treatment.

How Your Immune System Normally Works

Your body has immune cells called T cells that patrol your body looking for threats—including cancer cells. These T cells have "brakes" built into them that normally prevent them from attacking your own healthy cells. This is actually a good thing, because without these brakes, your immune system would attack everything, including normal tissue.

The Cancer Problem

Here's where cancer is clever: cancer cells have learned to flip the "off switch" on your T cells. They do this by displaying special proteins (like PD-L1 or CTLA-4) that tell your T cells to stop attacking. It's like the cancer cells are holding up a "do not disturb" sign that your immune system respects.

How Checkpoint Inhibitors Work

Checkpoint inhibitors are drugs that block these "off switches." They work by:

  1. Removing the brakes - The drugs bind to and block the checkpoint proteins (PD-1, PD-L1, CTLA-4, etc.)
  2. Reactivating T cells - Once the brakes are removed, your T cells can recognize cancer cells again
  3. Unleashing the attack - Your immune system can now fight the cancer cells directly

Think of it like removing a parking brake from a car—once it's off, the vehicle can move forward again.

Common Checkpoint Inhibitors

Different drugs target different checkpoints:

  • Anti-PD-1 inhibitors (like pembrolizumab, nivolumab)
  • Anti-PD-L1 inhibitors (like atezolizumab, durvalumab)
  • Anti-CTLA-4 inhibitors (like ipilimumab)

Why They Matter

According to NCCN Guidelines and ASCO recommendations, checkpoint inhibitors have become standard treatment options for many cancer types, including:

  • Melanoma
  • Non-small cell lung cancer
  • Certain head and neck cancers
  • Some kidney cancers
  • Bladder cancer
  • Certain blood cancers

Important Considerations

Because checkpoint inhibitors essentially "release the brakes" on your immune system, they can sometimes cause side effects where your immune system attacks healthy tissue (called immune-related adverse events). These can range from mild to serious and require monitoring by your healthcare team.

Questions to Ask Your Doctor

If checkpoint inhibitors are being considered for your care:

  1. Am I a candidate for checkpoint inhibitor therapy?
  2. Which specific checkpoint inhibitor would you recommend for my cancer type?
  3. What side effects should I watch for, and how will we monitor for them?
  4. How will we measure whether this treatment is working?
  5. How long would I typically receive this treatment?

For more detailed information, the National Cancer Institute (NCI) and American Cancer Society have excellent patient-friendly resources about immunotherapy on their websites.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Ask Navis about your case

That answer is general. Ask about your specific situation — no signup, answered right here.

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

Related Questions

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...

TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya

It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...

TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2

It is h3k27 altered dmg h3k27m negative, egfr a289v myc tp53 mgmt methylated

Your tumor has specific genetic changes H3K27, EGFR, MYC, TP53, MGMT that your doctors will use to guide treatment decisions—these findings help deter